Enspryng Faces an FDA Decision for Thyroid Eye Disease on October 15th With 1 Trial Won and 1 Lost

On October 15, 2026 the FDA is due to decide whether Enspryng, a monthly shot that patients give themselves at home, becomes the third approved drug for thyroid eye disease and the first that is not an infusion. The decision is unusual because the evidence is split down the middle. Genentech ran 2 trials built to the same blueprint, SatraGO-1 and SatraGO-2, in 258 people across 19 countries. One met its goal. The other did not. The company filed anyway, the FDA accepted the application and gave it priority review, and the FDA reissued a revised draft of its guidance for exactly this situation the same week.

What SatraGO-2 Proved About Enspryng in Thyroid Eye Disease

Thyroid eye disease is the autoimmune complication of Graves' disease in which the immune system inflames the fat and muscle behind the eyes, pushing the eyeballs forward, pulling the lids back and, in the worst cases, pinching the optic nerve. It affects somewhere between 90 and 300 people per 100,000 (NORD, 2024), and about half of people with an overactive thyroid get at least a mild form (Genentech, 2026). The active, inflamed phase lasts 6 months to 2 years before the disease burns out and leaves whatever damage it has done. Every drug trial in the field measures the same thing: how many patients see their eye bulging shrink by at least 2 millimeters, usually at week 24 (Lumvoa's trials used week 15), without the other eye getting worse.

By that measure SatraGO-2 was a clean win. In 48 people with active disease on Enspryng, 52.9% were responders against 23.4% of 49 on placebo, a gap of 28.9 points that would appear about 1 time in 900 if the drug did nothing (p = 0.0011). The secondary measures lined up behind it: 89.6% had their clinical activity score, the 7-point inflammation scale doctors use, fall by at least 2 points against 63.3% on placebo, 68.8% reached an inactive score of 0 or 1 against 40.8%, and 60.7% had their double vision improve by at least 1 grade against 25.8%. Average bulging dropped 1.97 mm on the drug and 0.96 mm on placebo (ClinicalTrials.gov NCT06106828).

The drug reached these numbers by a different road than the 2 approved treatments. Tepezza and Lumvoa block IGF-1R, a growth receptor on the orbital fibroblasts that swell the tissue behind the eye. Enspryng blocks the receptor for interleukin-6, an inflammatory messenger whose blood levels track with disease activity in thyroid eye disease and which drives the production of the thyroid-stimulating antibodies that start the whole process. The idea had been tested before Genentech got there: a 32-patient Spanish trial of tocilizumab, an older IL-6 receptor antibody, found that 93% of steroid-resistant patients had their inflammation score fall by 2 points against 59% on placebo (Perez-Moreiras et al., American Journal of Ophthalmology, 2018). Enspryng is tocilizumab's engineered descendant, built by Chugai with a "recycling" design that lets each antibody molecule bind the receptor repeatedly, which Genentech says gives sustained IL-6 inhibition.

SatraGO-1 enrolled the same kind of patient, used the same weight-tiered doses of 60, 120 or 180 mg at weeks 0, 2 and 4 and then every 4 weeks, and measured the same endpoint. Among 50 people on Enspryng, 49.0% were responders. Among 51 on placebo, 31.2% were. The 17.9-point gap carried a p-value of 0.0715, which is to say about a 7 in 100 chance that a difference that size could appear with a drug that does nothing, and the FDA's conventional line is 5 in 100 (ClinicalTrials.gov NCT05987423).

Genentech has not offered an explanation, and the posted data point to a plausible one that they cannot confirm. Enspryng performed almost identically in the 2 trials, 49% and 53%. Placebo did not: 31% in SatraGO-1 against 23% in SatraGO-2, and 20% and 10% in the 2 Tepezza trials, 5% and 8% in Lumvoa's. Thyroid eye disease improves on its own as the active phase ends, so if a trial happens to enroll people slightly later in that phase, or with milder swelling to begin with, it will see more placebo responders and a smaller gap; the posted results do not report the baseline differences that would settle whether that happened here. The average-change numbers say the same thing in a different way: on Enspryng, bulging fell 1.48 mm in SatraGO-1 and 1.97 mm in SatraGO-2, but on placebo it fell 1.31 mm in the first trial and only 0.96 mm in the second. The drug effect was there both times. The comparison group moved.

The miss was not total. In SatraGO-1 the inflammation score still fell by 2 or more points in 78.0% of Enspryng patients against 54.9% on placebo (p = 0.0120), 68.0% reached an inactive score against 45.1% (p = 0.0146), and when the trial's inactive-disease patients were added to the count, the proptosis response was 47.1% against 25.4% (p = 0.0070). Double vision did not separate, 44.4% against 34.4%. Genentech's press release uses a specific phrase for all of this: SatraGO-1 "offers additional confirmatory evidence." That phrase is not marketing. It is the vocabulary of the FDA rule that decides the case.

What the FDA Does With One Positive Trial of Two

The law has asked for "substantial evidence" of effectiveness since the 1962 drug amendments, and for decades the agency read that as 2 adequate and well-controlled trials. Congress loosened it in 1997 so that the standard "could also be met by a single trial plus confirmatory evidence," and the FDA's December 2019 draft guidance on the subject set out when 1 trial is enough, adding that "the degree of certainty supporting such a conclusion may differ, depending on clinical circumstances (e.g., severity and rarity of the disease and unmet medical need)" (Federal Register, December 20, 2019). A 2023 draft went further into what counts as confirmatory evidence, and on June 24, 2026, 5 days before Genentech announced that the FDA had accepted the Enspryng application, the FDA published a revised draft of the 2019 guidance that leans harder on the single-trial path.

Precedent cuts both ways. Tepezza itself was approved in January 2020 on 1 Phase 3 trial of 83 people plus a Phase 2 trial with a different primary endpoint, and an advisory committee voted 12 to 0 for it. The cautionary case is Aduhelm, the Alzheimer's antibody whose 2 twin trials split the same way, EMERGE positive and ENGAGE negative; the FDA approved it in June 2021 over its advisers' objections, on an accelerated pathway tied to a biomarker rather than on the clinical result, and Biogen withdrew it in 2024. Enspryng's application seeks traditional approval rather than accelerated approval, measured on eye bulging rather than a surrogate, which makes the question cleaner: does a strongly positive trial plus a trial that pointed the same way on every inflammation measure add up to substantial evidence? Priority review tells you the agency thought the question was worth 6 months rather than 10, not how it will answer.

Enspryng Against Tepezza and Lumvoa, Shot by Shot

The comparison patients will actually make is not against placebo. It is against the 2 drugs already on the shelf, and on the headline number Enspryng loses. In its pivotal trial Tepezza turned 83% of active-disease patients into proptosis responders against 10% on placebo, a 73-point gap; its Phase 2 trial found 71% against 20%. Lumvoa, approved June 26, 2026, reported 70% against 5% in active disease and 57% against 8% in chronic disease. Enspryng's 2 trials found 49% and 53%. No trial has compared the drugs directly, the placebo groups behaved very differently, and a responder rate is a crude yardstick, but the order is hard to argue with: the IGF-1R drugs move eye bulging more.

The other half of the comparison is what each drug asks of the patient. Tepezza is 8 intravenous infusions of 60 to 90 minutes, every 3 weeks for about 5 months, in an infusion center. Lumvoa is 5 infusions over 12 weeks. Enspryng, under its existing label, is a prefilled syringe or autoinjector that a patient or caregiver injects under the skin at home after training, with a loading series at weeks 0, 2 and 4 and then a dose every 4 weeks; in the thyroid eye disease trials that meant 7 injections in the first 24 weeks. Genentech is explicit that this is the pitch, describing the filing as "the first and only at-home subcutaneous treatment option" for the disease.

The Hearing Warning That Follows IGF-1R Drugs and Not Enspryng

The strongest argument for Enspryng is not on the efficacy chart. Both approved drugs carry a warning that they "may cause severe hearing impairment including hearing loss, which in some cases may be permanent." On Tepezza's label, hearing problems affected 10% of patients in the pivotal trials and 19% in 2 trials run after approval, and the warning was added in July 2023, more than 3 years after approval. Lumvoa's label, from its first day, reports hearing impairment in 15% of patients against 6% on placebo, plus muscle spasms in 40%, raised blood sugar in 13%, and menstrual changes in 29% of women. Both drugs block the same receptor, and the hearing warning has followed the class.

Enspryng has 6 years of use in NMOSD and more than 10,000 treated patients behind it, and its warnings are the ones that come with blocking IL-6: infections including serious ones, raised liver enzymes that need checking every 4 weeks for the first 3 months, lowered neutrophil counts, and hypersensitivity. Patients are screened for hepatitis B and tuberculosis before the first dose and cannot have live vaccines. In the SatraGO trials through week 24, serious adverse events occurred in 4.5% and 3.1% of Enspryng patients against 3.2% and 4.8% on placebo, with no deaths and no serious infections; SatraGO-2 did see more liver enzyme rises (6 against 1 for ALT) and more low neutrophil counts (4 against 1). Nothing about hearing appears in the adverse event tables of either trial. For a patient who is a musician, a teacher, or already hard of hearing, that difference may matter more than 20 points of responder rate.

What an Enspryng Approval, a Narrow Label or a Rejection Would Mean on October 15th

There is a fourth possibility that is really a version of the first: the FDA approves Enspryng and, in the same month, the field keeps moving under it. Viridian's elegrobart, an under-the-skin IGF-1R antibody, has already posted 2 positive Phase 3 trials (54% to 63% responders against 18% in active disease) and is headed for its own filing in the first quarter of 2027, and Amgen's on-body subcutaneous version of Tepezza hit 76.7% against 19.6% in its Phase 3. Within 2 years the at-home advantage Enspryng is filing on may belong to 3 drugs. What would still be Enspryng's alone is the mechanism and the absence of a hearing warning.

Thyroid Eye Disease Clinical Trials Recruiting Now

The SatraGO trials are complete, so there is no way to get Enspryng for thyroid eye disease through a study today. The recruiting pipeline as of October 2026 is thinner than the number of drugs suggests, because 2 of the most-watched programs failed: Immunovant's batoclimab missed its primary endpoint in both Phase 3 trials, and argenx stopped its 2 efgartigimod trials for futility in December 2025, although it has since registered 2 new Phase 3 studies, 1 of them at 21 US sites (NCT07570316). Sling Therapeutics started the Phase 3 trial of linsitinib, an oral IGF-1R blocker, in August 2026 (NCT07753603). The thyroid eye disease trials page lists what is recruiting, and the trials near me tool maps the sites.